Department of Hematology, The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China.
Institute of Hematology, Zhejiang University, Hangzhou, China.
Sci Rep. 2017 Apr 28;7:45960. doi: 10.1038/srep45960.
Huntingtin interacting protein 1 (HIP1) is an endocytic protein which is overexpressed in a variety of human cancers and involved in cancer-causing translocation in leukemia. However, the prognostic impact of HIP1 expression on AML remains unclear. In this study, quantification of HIP1 transcript by real-time quantitative PCR in bone marrow blasts was performed in 270 AML patients. As a result, high HIP1 expression was seen more frequently in older patients, M4/M5 morphology and genes of NPM1 and DNMT3A mutations, and underrepresented in favorable karyotype subgroups and CEBPA double allele mutations in our AML patients. We also found high HIP1 expressers showed lower levels of hemoglobin. In addition, overexpression of HIP1 was associated with an inferior overall survival. The prognostic value of HIP1 expression was validated in patients from an independent TCGA cohort. Notably, up-regulation of miR-16, miR-15a, miR-28 and miR-660 were seen in high HIP1 expressers from the two independent cohorts. In vitro, interfereing of HIP1 expression by siRNA suppressed the proliferation of leukemic cells, and downregulation of these miRNAs were seen in THP-1 and Kasumi cell lines after silencing HIP1 expression. In conclusion, the HIP1 gene expression might serve as a reliable predictor for overall survival in AML patients.
亨廷顿蛋白相互作用蛋白 1(HIP1)是一种内吞蛋白,在多种人类癌症中过度表达,并参与白血病中的致癌易位。然而,HIP1 表达对 AML 的预后影响尚不清楚。在这项研究中,对 270 例 AML 患者的骨髓母细胞中 HIP1 转录物进行了实时定量 PCR 定量。结果显示,HIP1 高表达在老年患者、M4/M5 形态、NPM1 和 DNMT3A 基因突变的基因中更为常见,在我们的 AML 患者中,在有利核型亚组和 CEBPA 双等位基因突变中表达较低。我们还发现高 HIP1 表达者的血红蛋白水平较低。此外,HIP1 的过表达与总体生存不良相关。HIP1 表达的预后价值在来自独立 TCGA 队列的患者中得到了验证。值得注意的是,在来自两个独立队列的 HIP1 高表达者中观察到 miR-16、miR-15a、miR-28 和 miR-660 的上调。在体外,通过 siRNA 干扰 HIP1 表达抑制了白血病细胞的增殖,并且在沉默 HIP1 表达后,在 THP-1 和 Kasumi 细胞系中观察到这些 miRNAs 的下调。总之,HIP1 基因表达可能是 AML 患者总体生存的可靠预测指标。